Moderna Moves Forward With Second HIV Vaccine Trial

Moderna Inc MRNA has dosed the first participant in a clinical trial of an experimental human immunodeficiency virus (HIV) trimer mRNA vaccine (mRNA-1574).
The open-label, multicenter, randomized Phase 1 trial (HVTN 302) is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines.
The primary hypothesis is that the soluble and membrane-bound HIV envelope trimer mRNA vaccines will be safe and well-tolerated by HIV-uninfected individuals and elicit autologous neutralizing antibodies.
The trial is expected to enroll approximately 100 HIV-negative adults aged 18 to 55 years.
Related: IAVI, Moderna Kickstart HIV Vaccine Antigens Trial Delivered Through mRNA Technology.
The trial is sponsored and funded by the Division of AIDS (DAIDS) of the National Institute of Allergy and Infectious Diseases (NIAID) within the National Institutes of Health (NIH).
Moderna is advancing two HIV preventative vaccine strategies based on germline targeting and immune-focusing approaches.
In addition to this HIV trimer mRNA vaccine trial of mRNA-1574, Moderna is partnering to test HIV vaccine antigens mRNA-1644 and mRNA-1644v2-Core, being evaluated in a Phase I trial sponsored by IAVI and supported by the Bill & Melinda Gates Foundation.
Price Action: MRNA shares are up 13% at $156.46 during the market session on the last check Monday.

Momentum6.31

GrowthNot Available

QualityNot Available

Value69.07

Short

Medium

Long